IL6 and psoriatic arthritis: In a randomized, double-blind, placebo-controlled, dose-ranging study in 165 patients with active psoriatic arthritis and an inadequate response to nonsteroidal anti-inflammatory drugs, the safety profile was consistent with the pharmacology of IL-6 blockade39.